abstract |
The present invention provides RNA interference to silence TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression or to inhibit tumor necrosis factor α (TNFα) by silencing TNFα converting enzyme (TACE / ADAM17) mRNA expression. do. Silencing the TNFα target is particularly useful for treating patients with or at risk of developing TNFα-related symptoms such as dry eye, allergic conjunctivitis, or eye inflammation, or dermatitis, rhinitis, or asthma. Do. |